Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK).
G. J. Fetterly
No relevant relationships to disclose
K. E. Thudium
No relevant relationships to disclose
J. Kalabus
No relevant relationships to disclose
M. Murphy
No relevant relationships to disclose
P. D. Zagst
No relevant relationships to disclose
J. Prey
No relevant relationships to disclose
E. Kittleman
No relevant relationships to disclose
A. A. Adjei
No relevant relationships to disclose
T. L. O'Connor
No relevant relationships to disclose
J. G. Blanco
No relevant relationships to disclose